dBET1 is primarily used in biomedical research, particularly in the field of targeted protein degradation. It functions as a PROTAC (Proteolysis Targeting Chimera) molecule, designed to degrade specific proteins of interest. This compound is especially valuable in studying and treating diseases like cancer, as it can selectively degrade proteins involved in tumor growth and survival. By leveraging the ubiquitin-proteasome system, dBET1 effectively removes target proteins, offering a novel approach to drug development and therapeutic intervention. Its application extends to understanding protein function and signaling pathways, aiding in the discovery of new treatment strategies.